Navigation Links
Santaris Pharma A/S Forms Strategic Alliance With Shire plc to Develop RNA-Based Medicines for the Treatment of Rare Genetic Disorders
Date:8/24/2009

HOERSHOLM, Denmark, August 24 /PRNewswire/ --

- Santaris Pharma A/S and Shire plc to Engage in a Multi-Year Research Program Utilizing Santaris Pharma's Proprietary Locked Nucleic Acid (LNA) Drug Platform to Identify and Select Drug Candidates Against Certain Targets for the Treatment of Rare Genetic Disorders

- Santaris Pharma A/S to Receive Significant Upfront Payments, Milestone Payments and Royalties for Providing Access to its LNA Technology, Exclusivity for Three Pre-Defined Targets and Funding for Discovery

- Partnership for the Treatment of Rare Genetic Disorders Further Demonstrates Versatility of the LNA Drug Platform to Develop RNA-Based Medicines for a Range of Disease Areas Including Metabolic Disorders, Cancer, Infectious and Inflammatory Diseases

Santaris Pharma A/S, a privately-held biopharmaceutical company focused on developing RNA-based drugs targeted to disease-related mRNAs and microRNAs, today announced a multi-year worldwide strategic alliance with Shire plc to discover and develop new RNA-based medicines to treat rare genetic disorders.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090420/344344 )

The alliance will use Santaris Pharma A/S' proprietary Locked Nucleic Acid (LNA) Drug Platform to identify and select drug candidates against certain targets. Shire will be responsible for the selection of appropriate drug candidates, as well as further development and commercialization of products arising from the alliance.

Under the terms of the agreement Santaris Pharma A/S will receive initial early stage payments of US$6.5 million covering technology access, exclusivity for three pre-defined targets and initial discovery funding, and an additional early stage payment of US$13.5 million upon successful completio
'/>"/>

SOURCE Santaris Pharma A/S
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009
2. Santaris Pharma Director Appointed Adjunct Professor in RNA Biology at the University of Aalborg, Denmark
3. Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule
4. Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008
5. Amylin Pharmaceuticals Board of Directors Elects Paulo F. Costa Chairman of the Board
6. Angiotech Pharmaceuticals announces the commercial launch of the Option(TM) Inferior Vena Cava Filter in the United States
7. Epix Pharmaceuticals, Inc. Announces the PRX-08066 Therapeutics Program in Phase 2 for Respiratory Indication Will Be Part of The Intellectual Property Offered for Sale at the September 30, 2009 Auction
8. Pre-Owned Prices on Premium Pharmaceutical Equipment
9. Laureate Pharma Elects New Board Member
10. CBI Hosts 5th Annual Pharma/Biotech Enterprise Governance, Risk and Controls Congress
11. PharmaTelevision Launches the First Daily News Show for the Life Sciences Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... For the fifth time since 2006, ExakTime ... of the fastest-growing companies. , “We’re so proud that ExakTime’s ... Inc. Magazine,” ExakTime CEO Tony Pappas said. , ExakTime earned ... three-year growth rate of 61 percent from 2010 to 2013 ... than 40 percent. , Pappas cited strong performance in the ...
(Date:9/23/2014)... -- Age Defying Dermatology ® , owned and operated by ... the first clinics in the Bay Area to offer ... removal. The treatment safely and effectively erases tattoos with ... has been a lengthy, painful, and all too often ... to erase tattoo pigment more efficiently with far less ...
(Date:9/23/2014)... Cambridge Semantics, the leading provider of ... named in the recent ‘Hype Cycle for Life Sciences ... report details key insights pertaining to the benefits in ... analysts Michael Shanler and Stephen Davies, “The use of ... relationships with scientific stakeholders, and support collaboration and innovation ...
(Date:9/23/2014)... Marktech Optoelectronics has introduced the MTE280xxx series, ... the 280 nm wavelength range. This series joins Marktech’s ... 280nm to 405nm. These new devices are suitable for ... curing. Mark Campito, Marktech’s CEO states that “what makes ... is that we offer it in one of the ...
Breaking Biology Technology:ExakTime Makes Inc. 5000 List for the Fifth Time 2Age Defy Now Offers World's Most Advanced Technology for Tattoo Removal 2Cambridge Semantics Identified in Gartner’s ‘Hype Cycle for Life Sciences 2014’ Report 2Marktech Introduces its New Line of Deep UV Emitters 2
... screening initiative launches in Atlanta and continues for 90 days;, ... in 13 cities ... across the country, ... specialty biopharmaceutical company, today,announced the launch of a 13-city mobile screening ...
... to Impact Lung Cancer Care, ST. LOUIS, ... start-up company, has secured $4.75M in venture capital ... delivery system for minimally,invasive biopsy and ablation of ... was joined by Advantage Capital Partners and existing ...
... EuroPCR08 will highlight choice of different modalities ... available on single integrated imaging platform., SAN DIEGO, ... VOLC ), a leading manufacturer and developer of,intravascular ultrasound ... designed to enhance the diagnosis and,treatment of coronary and ...
Cached Biology Technology:Shire Launches Nationwide Adult ADHD Mobile Awareness Tour 2Shire Launches Nationwide Adult ADHD Mobile Awareness Tour 3Shire Launches Nationwide Adult ADHD Mobile Awareness Tour 4Shire Launches Nationwide Adult ADHD Mobile Awareness Tour 5Veran Medical Technologies Secures $4.75M in First Institutional Funding 2Volcano Announces Placement of 1,000th s5 and s5i IVUS Imaging System 2Volcano Announces Placement of 1,000th s5 and s5i IVUS Imaging System 3Volcano Announces Placement of 1,000th s5 and s5i IVUS Imaging System 4
(Date:9/23/2014)... has domesticated animals, selecting the best traits possible ... an intriguing animal to examine adaptation to climate ... selected breeding and a wealth of livestock genome-wide ... study that combined molecular and environmental data, professor ... genes under environmental selection from domesticated sheep breeds. ...
(Date:9/23/2014)... at the University of Wisconsin-Madison and the Morgridge Institute ... to screen for neural toxins, helping flag chemicals that ... Health (NIH) announced today that the UW-Madison and Morgridge ... the promising work as part of the Tissue Chip ... $7 million over the three-year project. , The ...
(Date:9/23/2014)... new tissues during the healing process, cells must ... years, scientists believed this communication happened primarily through ... and the University of Pittsburgh have found that ... if not more crucial. The findings, published in ... the National Academy of Sciences , could lead ...
Breaking Biology News(10 mins):Being sheepish about climate adaptation 2UW-Madison team developing 'tissue chip' to screen neurological toxins 2UW-Madison team developing 'tissue chip' to screen neurological toxins 3The mechanics of tissue growth 2
... anything they want and never gain a pound, while others ... You may be seeing things correctly after all. According ... Genetics ( http://www.genetics.org ), this may have a biological ... with diet, rather than diet alone, are the main cause ...
... (CLOTS)an intensive five-day course offered by the Society ... interventional radiologists, neurointerventionalists, vascular neurologists and fellows-in-training with ... discuss all aspects of acute stroke management. ... in the United States, with about 600,000 new ...
... Just as cooking helps people digest food, pretreating polycarbonate ... of its bisphenol A (BPA) content may be ... eco-friendly way, scientists have found. Their new study is ... Mukesh Doble and Trishul Artham note that manufacturers produce ...
Cached Biology News:Why fad diets work well for some, but not others 2Explore stroke care with Society of Interventional Radiology's CLOTS 2
CBF-B (G-2)...
... B Receptor Like Protein 2 ... (ETBR-LP-2) has been reported in human ... human brain and colon libraries. ... the amino acid sequence is considered ...
HSV-2 gD (0191)...
... The epitope recognized by A300-183A ... isoform 5 of human quaking ... (GeneID 9444). The epitope ... 1, 2, 3, 4, 6, ...
Biology Products: